This story is a standalone deepdive that connects to two ongoing threads: Universities of the Republic — Act IV (where Niprisan is catalogued among the things the decay could not stop) and Industries the Republic Built and Lost. It is one of the rare cases where a Nigerian university laboratory produced a finished, patented, clinically-validated pharmaceutical product — and the rarer case of that product reaching the market under a Nigerian-owned commercial partner. It is also, in the end, a story about why almost none of these breakthroughs are sustained.
## What Niprisan actually was
Niprisan (later branded Nicosan) is a standardised herbal anti-sickling compound developed at the National Institute for Pharmaceutical Research and Development (NIPRD), Idu, Abuja — an institute that grew out of the pharmacology and pharmacognosy traditions of the University of Ibadan and Obafemi Awolowo University. The lead investigator was Professor Charles Wambebe, working from a Nupe traditional-medicine formulation supplied by a herbalist, Reverend P.O. Ogunyale, in the late 1980s.
The compound is a four-plant aqueous extract — *Piper guineense* (West African black pepper) seeds, *Pterocarpus osun* (camwood) stems, *Eugenia caryophyllata* (clove) buds, and *Sorghum bicolor* (guinea-corn) leaves. NIPRD spent roughly a decade on what is now an unusual sequence for African pharma: bioassay-guided fractionation, animal toxicology, formal Phase I / Phase IIA / Phase IIB clinical trials at the National Hospital Abuja and the University of Maiduguri Teaching Hospital, and US patent filing.
**US Patent 5,800,819** ('Herbal Composition for the Treatment of Sickle Cell Anaemia', Wambebe et al., 1 September 1998) was granted to NIPRD — the first US patent ever awarded to a Nigerian federal research institute for a finished drug.
## What the trials showed
Published results across the 1996–2001 trials (and later peer-reviewed in *Journal of Ethnopharmacology* and *Phytomedicine*) reported, for sickle-cell patients in steady state:
- A reduction in the frequency of acute painful crises from a median of about 7 per year to between 0 and 2 per year for most patients on the compound.
- A reduction in hospitalisation days of roughly 70 percent.
- No significant haematological or hepatic toxicity at the standardised dose over twelve months.
This is not a cure; it is a crisis-prevention drug — and in a country with the world's largest absolute population of sickle-cell sufferers (roughly 4 to 6 million homozygotes, with about 150,000 SS births per year), a crisis-prevention drug is a public-health instrument of the first order.
## The commercial chapter
In 2002 NIPRD licensed Niprisan to Xechem Nigeria Limited, a Lagos-based subsidiary of Xechem International (US), founded by the Nigerian-American chemist Dr Adenike Adeyeye and Dr Ramesh Pandey. Production began at a facility in Abuja and the drug was marketed under the trade name Nicosan from 2006. For roughly three years it was on the shelves of pharmacies in Abuja, Lagos, Port Harcourt and Kano; a small export programme reached the United States under FDA orphan-drug designation (granted 2004).
Then, between 2008 and 2011, it stopped.
The collapse had four causes, none of them scientific:
- Capital. Xechem Nigeria could not raise the working capital for sustained production after the 2008 financial crisis dried up its US parent's funding line; the Bank of Industry loan facility it had drawn on went non-performing.
- Royalty dispute. NIPRD and Xechem fell into a multi-year disagreement over royalty payments and quality-control oversight; production was suspended pending resolution.
- Regulatory drift. The orphan-drug designation in the US was not converted to a full New Drug Application because the Phase III trial — required by the FDA — was never funded.
- No successor. When Xechem Nigeria was wound up in 2011, no Nigerian pharmaceutical company (May & Baker, Emzor, Fidson, GSK Nigeria) acquired the licence. Brief revival talks in 2014 and 2019 produced no production.
As of 2026, Niprisan is not commercially available. Sickle-cell patients in Nigeria who can afford it import hydroxyurea (an older, harsher drug developed in the United States in the 1960s) or, increasingly, the new American gene-therapy products at hundreds of thousands of dollars per course.
## Why this is the F.O.O.D. story
The writer of F.O.O.D. in plain sight — defensive capacity makes the point that a country with the agronomic, geological and human-capital base of Nigeria should, by any reasonable benchmark, be carrying out continuous applied research on the things it already produces in quantity — cement, palm oil, cassava, cocoa, gum arabic, shea, limestone, natural gas, even sand. The breakthroughs are not the problem. The breakthroughs exist. What is missing is the institutional capacity to *sustain* them past the first commercial cycle.
Niprisan is the proof of concept and the proof of failure, in the same molecule.
A full catalogue of the other Nigerian-laboratory breakthroughs that meet the same criterion — drugs, cultivars, vaccines, mathematics, engineering, genomics — is collected at the Nigerian Breakthroughs hub, with a deepdive page for each entry.
## The pattern
The breakthrough is almost never the bottleneck. The bottleneck is, in this order: (i) the absence of patient capital willing to fund a Phase III trial or a second production run, (ii) the absence of a federal procurement guarantee that would let a Nigerian-made drug or seed or cement reach a guaranteed buyer, (iii) the institutional fragility of the research bodies themselves, where a single VC, MD or DG turnover can suspend a programme indefinitely, and (iv) an import regime that treats foreign equivalents as default and Nigerian equivalents as suspect.
The F.O.O.D. argument is the right frame: a country that can engineer a sickle-cell drug from a Nupe village remedy and patent it in the United States can engineer almost anything, given the chance to do it twice.